BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19734106)

  • 1. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology.
    Pistis F; Guedea F; Pera J; Gutierrez C; Ventura M; Polo A; Martinez E; Boladeras A; Ferrer F; Gabriele P; Linares L
    Brachytherapy; 2010; 9(1):15-22. PubMed ID: 19734106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.
    Sato M; Mori T; Shirai S; Kishi K; Inagaki T; Hara I
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1002-9. PubMed ID: 18448272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose-rate brachytherapy with external beam radiotherapy for localized or locally advanced prostate cancer].
    Matsunobu A; Shioyama Y; Uehara S; Ohga S; Atsumi K; Matsumura T; Sakamoto N; Yoshikawa M; Iguchi A; Honda H
    Fukuoka Igaku Zasshi; 2010 Apr; 101(4):75-83. PubMed ID: 20715564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan.
    Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH
    Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
    Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.